Trial Profile
A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Zatolmilast (Primary)
- Indications Fragile X syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Tetra Therapeutics
- 15 Feb 2023 Planned End Date changed from 30 Nov 2023 to 1 Jul 2024.
- 15 Feb 2023 Planned primary completion date changed from 30 Aug 2023 to 1 Feb 2024.
- 12 Jul 2022 According to a Tetra Therapeutics media release, Elizabeth M. Berry-Kravis, M.D., Ph.D., Rush University Medical Center, Chicago, Illinois is the principal investigator for the trial.